Utama › Gangguan Depresi Major › Connecticut
Kajian klinikal Gangguan Depresi Major di Connecticut
16 kajian untuk Gangguan Depresi Major sedang mencari peserta di lokasi di Connecticut.
Bandar di Connecticut
Teks kajian rasmi (Bahasa Inggeris)
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- UConn Health Center, Farmington
Mengambil pesertaFasa 3
Umur 18 hingga 74 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06559306Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Connecticut Health Center, Farmington
Mengambil pesertaFasa 3
Umur 18 hingga 65 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05850689A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Yale School of Medicine - Yale Program for Psychedelic Science, New Haven
Mengambil pesertaFasa 3
Umur 18 hingga 85 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06793397A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Cromwell
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT07065240A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Institute of Living, Hartford
Mengambil pesertaFasa 3
Umur 18 hingga 74 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07076407A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Yale University School of Medicine, New Haven
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT07412756A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Ct Clinical Research Associates, Cromwell
Mengambil pesertaFasa 3
Umur 18 hingga 74 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- University of Connecticut School of Medicine Psychiatry Department, Farmington
Mengambil pesertaFasa 2
Umur 18 hingga 64 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06547489A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, New Haven
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Jul 2026 · NCT07196501Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Cromwell
- Neurocrine Clinical Site, Farmington
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Jul 2026 · NCT06966401The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
- VA Connecticut Healthcare System, West Haven
Mengambil pesertaFasa 2
Umur 21 hingga 65 · Semua jantina · Dikemas kini 6 Mei 2026 · NCT05786066Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
- Yale University, New Haven
Mengambil pesertaFasa 1
Umur 18 hingga 60 · Semua jantina · Dikemas kini 6 Mei 2026 · NCT05915013Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- Hartford Hospital, Hartford
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 40 · Semua jantina · Dikemas kini 10 Mac 2026 · NCT06740383Imaging Depression in Parkinson's Disease
- Yale University, New Haven
Mengambil pesertaFasa 2Sukarelawan sihat dialu-alukan
Umur 40 hingga 80 · Semua jantina · Dikemas kini 10 Mac 2026 · NCT06402955Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #122, Cromwell
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 20 Jan 2026 · NCT06633016Study of ALTO-300 in MDD
- Site 214, Norwalk
Mengambil pesertaFasa 2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 24 Jul 2025 · NCT05922878Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.